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OBJECTIVEdTo investigate the relationship between arterial stiffness and low-grade inflam-
mation in subjects with type 1 diabetes without clinical cardiovascular disease.
RESEARCH DESIGN AND METHODSdSixty-eight patients with type 1 diabetes and
68 age- and sex-matched healthy subjects were evaluated. Arterial stiffness was assessed by aortic
pulse wave velocity (aPWV). Serum concentrations of high-sensitivity C-reactive protein
(hsCRP), interleukin (IL)-6, and soluble fractions of tumor necrosis factor-a receptors 1 and 2
(sTNFaR1 and sTNFaR2, respectively) were measured. All statistical analyses were stratified
by sex.
RESULTSdSubjects with diabetes had a higher aPWV compared with healthy control subjects
(men: 6.9 vs. 6.3 m/s, P, 0.001; women: 6.4 vs. 6.0 m/s, P = 0.023). These differences remained
significant after adjusting for cardiovascular risk factors. Men with diabetes had higher concen-
trations of hsCRP (1.2 vs. 0.6 mg/L; P = 0.036), IL-6 (0.6 vs. 0.3 pg/mL; P = 0.002), sTNFaR1
(2,739 vs. 1,410 pg/mL; P, 0.001), and sTNFaR2 (2,774 vs. 2,060 pg/mL; P, 0.001).Women
with diabetes only had higher concentrations of IL-6 (0.6 vs. 0.4 pg/mL; P = 0.039). In men with
diabetes, aPWV correlated positively with hsCRP (r = 0.389; P = 0.031) and IL-6 (r = 0.447; P =
0.008), whereas in women with diabetes no significant correlation was found. In men, multiple
linear regression analysis showed that the following variables were associated independently with
aPWV: age, BMI, type 1 diabetes, and low-grade inflammation (R2 = 0.543). In women, these
variables were age, BMI, mean arterial pressure, and type 1 diabetes (R2 = 0.550).
CONCLUSIONSdArterial stiffness assessed as aPWV is increased in patients with type 1
diabetes without clinical cardiovascular disease, independently of classical cardiovascular risk
factors. In men with type 1 diabetes, low-grade inflammation is independently associated with
arterial stiffness.
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I t is well established that type 2 diabetesis a risk factor for cardiovascular dis-ease. However, it is less well known
that the relative risk of cardiovascular
disease in type 1 diabetes can be as much
as 10-fold greater than in the healthy
population, especially in women (1), being
even greater than in type 2 diabetes (2).
Consequently, cardiovascular disease is
the major cause of mortality in type 1 di-
abetes (2). Diabetes results in an acceler-
ated arteriosclerotic process, which is not
fully explained by classical cardiovascular
risk factors. As a result, the pathophysio-
logical mechanisms underlying cardio-
vascular events in type 1 diabetes are
not completely understood.
Arterial stiffness is an early sign of
arteriosclerosis (3), and its study would
be appropriate for investigating the arte-
riosclerotic mechanisms long before any
cardiovascular event occurs. Arterial stiff-
ness predicts cardiovascular events inde-
pendently of classical cardiovascular risk
factors in several populations (see below).
Therefore, it can be assumed that it reflects
the deleterious effect of all cardiovascular
risk factors (known and unknown) on the
arterial wall. The gold standard for measur-
ing central arterial stiffness is aortic pulse
wave velocity (aPWV), according to a re-
cent consensus (4). aPWV independently
predicts cardiovascular events and mortal-
ity in the general population, in the elderly,
in hypertensive individuals, in subjects
with end-stage renal failure, and in subjects
with type 2 diabetes (5).
Finally, little is known regarding fac-
tors involved in the pathophysiology of
arterial stiffness in type 1 diabetes. One of
these factors could be low-grade inflam-
mation. High-sensitivity C-reactive protein
(hsCRP) is the most established down-
stream marker of low-grade inflamma-
tion and has been reported to be a strong
predictor of cardiovascular outcomes (6).
The primary proinflammatory cytokines
interleukin (IL)-6 and tumor necrosis fac-
tor (TNF)-a are the main inducers for the
hepatic synthesis of hsCRP (7). Although
there is less evidence in comparison with
hsCRP, both of them also have been asso-
ciated with the prediction of cardiovascular
outcomes (8–10). Low-grade inflammation
also has been associated with the develop-
ment of both micro- and macrovascular
complications in type 1 diabetes (11). In-
deed, low-grade inflammation impairs en-
dothelial function and has been associated
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with an increase in aPWV in healthy sub-
jects (12), in hypertensive individuals
(13), and in subjects with chronic kidney
disease (14) or with metabolic syndrome
(15). No such evidence exists in type 1
diabetes; however, recently an activation
of the TNFa system has been reported in
association with an increase in brachial
PP, a subrogate marker of arterial stiffness,
in normotensive subjects with type 1
diabetes (16).
Our main objective was to evaluate
aPWV as ameasure of arterial stiffness in a
group of subjects with type 1 diabetes
without clinical cardiovascular disease
and to explore its relationship with bio-
markers of low-grade inflammation. Be-
cause the role of low-grade inflammation
in the atherosclerotic process seems to be
different in men and women (17), our
study was stratified by sex, and the sam-




type 1 diabetes (34 men and 34 women),
aged 18–65 years, and 68 age- and sex-
matched healthy subjects were included
in our study. None of them had any con-
dition associated with an inflammatory
response (e.g., acute or chronic inflam-
matory infectious diseases) or had re-
ceived anti-inflammatory treatment in
the previous 6 months. None of them
had any clinical cardiovascular disease.
Subjects with type 1 diabetes were con-
secutively recruited from our outpatient
clinic, and all had at least 1 year of duration/
evolution of diabetes. The control group
was recruited from hospital staff members
and their relatives and friends.
After an overnight fast, venous blood
samples were taken, and aliquots of
plasma and serum were stored at 2808C
until processing. In women, all measure-
ments were conducted during the follic-
ular phase of the menstrual cycle. The
following information was recorded
using a predefined standardized form:
sex, age, diabetes duration, BMI, waist-
to-hip ratio, systolic and diastolic blood
pressure (SBP and DBP, respectively), and
mean arterial pressure (MAP; defined as
1/3 SBP + 2/3 DBP2 physical activity [In-
ternational Physical Activity Question-
naire], cigarette smoking, alcohol intake,
insulin dose or the use of any other med-
ical treatment, HbA1c, lipid profile, serum
concentrations of hsCRP, IL-6, soluble
fractions of the TNFa receptors 1 and 2
[sTNFaR1 and sTNFaR2, respectively],
and microvascular complications [only
in the cases]). Hypertension was defined
as having blood pressure.140/90 mmHg
(18) and/or being under antihypertensive
treatment. Dyslipidemia was defined as
having concentrations of total cholesterol
.5.2mmol/L, triglycerides.1.7mmol/L,
HDL cholesterol ,1.03 mmol/L, LDL
cholesterol .3.4 mmol/L (19), and/or re-
ceiving drug treatment for dyslipidemia.
The study protocol was approved by
our hospital’s ethics committee and was
conducted according to the principles of
the Declaration of Helsinki. All subjects
gave their informed consent before par-
ticipating in the study.
Assessment of microvascular
complications
Peripheral polyneuropathy was assessed
through a previously described two-step
protocol combining the 15-item Michi-
gan Neuropathy Screening Instrument
and a physical examination evaluation
(16). Retinopathy was classified according
to the data from our department data-
base. Subjects were classified into the fol-
lowing three groups according to the
degree of retinopathy: no retinopathy,
nonproliferative retinopathy, or prolifer-
ative retinopathy. Nephropathy was
evaluated by the measurement of urinary
albumin excretion. Subjects with a uri-
nary albumin-to-creatinine ratio .3.4
mg/mmol (20), or those who previously
were treatedwith converting enzyme inhib-
itors or angiotensin receptor blockers
(for microalbuminuria or macroalbumi-
nuria), were considered as having dia-
betic nephropathy.
Assessment of arterial stiffness
Measurement of aPWV. We measured
brachial blood pressure three times with
the subjects in a sitting position; the mean
of the last two measurements was used in
all calculations. Subjects rested in the supine
position, and measurements were taken
immediately after the determination of
blood pressure in accordance with the
recommendations of the recent consensus
on arterial stiffness (4). Subjects were
asked to refrain from smoking and from
eating or taking caffeine beverages at least
3 h before measurements. aPWV was de-
termined by sequential applanation to-
nometry (Millar tonometer, SPC-301;
Millar Instruments, Houston, TX) at the
carotid and femoral arteries gated to a
three-lead electrocardiogram using the
SphygmoCor device (SphygmoCor; AtCor,
Sydney,Australia). Timedelaywas calculated
using a foot-of-the-wavemethod. The sur-
face distance from the suprasternal notch
to each recording site was measured. The
total transit distance was calculated by
subtracting the sternal notch to carotid
distance from the sternal notch to femoral
distance. aPWV was calculated using the
total transit distance divided by the time
delay. aPWVs not achieving the automatic
quality controls specifiedby theSphygmoCor
software were rejected. The mean of two
aPWV measurements was taken for each
subject for all calculations. Data were




liquid chromatography (Menarini Diag-
nostics, Firenze, Italy). Total serum cho-
lesterol, triglycerides, HDL cholesterol,
and LDL cholesterol were measured us-
ing standard enzymatic methods. hsCRP
was determined by immunonephelometry
(Siemens,Munich, Germany). IL-6was de-
termined by enzyme-linked immunosor-
bent assay (R&D Systems, Oxon, U.K.) as
were sTNFaR1 (Hycultbiotech, Uden,
The Netherlands) and sTNFaR2 (R&D
Systems).
Statistical analyses
We calculated that the number of subjects
needed to find a difference of 0.5 m/s in
aPWV between men and women with
type 1 diabetes and their respective con-
trol subjects would be 34 in each of the
four groups (a = 0.05 and b = 20%). Data
are presented as percentages, means (SD)
for variables normally distributed, or me-
dians (interquartile range) for variables
not normally distributed. All data were
tested for normality using the Kolmogorov-
Smirnov test. To improve skewedness
and kurtosis, variables not normally dis-
tributed were log transformed. The
analyses were performed stratified by
sex. Differences between patients with
type 1 diabetes and control subjects
were analyzed using the x2 test for com-
parisons of proportions and unpaired
t tests or Mann-Whitney U tests for com-
parisons of quantitative variables, as
needed. In both men and women, we as-
sessed the potential relationships between
arterial stiffness and all inflammatory-
related serum proteins evaluated through
univariate, nonparametric correlations
and linear regression models to adjust
for potential confounders. Variables for
linear regression analyses were selected
based on univariate correlation analyses
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and those variables known or likely to be
associated with arterial stiffness. In the fi-
nal model, the variables included for both
sexes were age, smoking status, physical
activity, hypertension (no/yes), dyslipid-
emia (no/yes), BMI, MAP, total cholesterol,
log triglycerides, logHDL cholesterol, type
1 diabetes, and low-grade inflammation.
Because inflammatory-related serum pro-
teins only were measured once, the associ-
ation (if any) of low-grade inflammation
with arterial stiffness would tend to be un-
derestimated. To address this issue, a z score
was calculated for each inflammatory-
related serum protein evaluated as the
following: (value in the individual 2
mean value in the study population)/SD.
Subsequently, the low-grade inflamma-
tion general score was calculated as the
following: (z score of hsCRP + z score of
IL-6 + z score of sTNFaR1 + z score of
sTNFaR2)/4. In addition, it is reasonable
to consider that the integrated information
obtained using these four selected proin-
flammatory markers is better than if we
had used each parameter separately. The
IBM SPSS Statistics (version 19 for Macin-
tosh; IBM, Armonk, NY) was used for all
calculations. All P values were two sided,
and a P value ,0.05 was considered sta-
tistically significant.
RESULTSdWe evaluated 68 patients
with type 1 diabetes and 68 age- and sex-
matched healthy subjects (n = 136). Their
clinical and analytical characteristics are
shown in Table 1 for men and Table 2
for women. Of 136 subjects, 8 were on
antihypertensive drugs (7 patients and 1
control subject), 15 were on statins (14
patients), and 6were on antiplatelet drugs
(all with diabetes). A total of 13 patients
were on levothyroxine treatment (8 with
diabetes; range dose 25–150 mg/day), but
all had normal serum concentrations of
thyroxin and thyrotropin.
Subjects with type 1 diabetes, com-
pared with healthy control subjects,
showed higher values of fasting plasma
glucose and HbA1c. Men with type 1 di-
abetes were more hypertensive than con-
trol subjects and had higher values of SBP.
Women with type 1 diabetes presented
higher BMI values. Subjects with type 1
diabetes presented a better nonsignificant
lipid profile than control subjects, proba-
bly as a result of the significant number of
patients treated with statins.
Subjects with type 1 diabetes (men
and women) had a higher aPWV com-
pared with their respective control sub-
jects (men: 6.9 m/s [6.5–7.9] vs. 6.3 m/s
[5.7–6.7], P , 0.001; women: 6.4 m/s
[5.9–7.5] vs. 6.0 m/s [5.3–6.7], P =
0.023). These differences remained sig-
nificant after adjusting for classical car-
diovascular risk factors (age, physical
activity, smoking status, hypertension,
dyslipidemia, and BMI) in both sexes
(men: P = 0.001; women: P = 0.025).
Men with type 1 diabetes showed higher
serum concentrations of hsCRP, IL-6,
sTNFaR1, and sTNFaR2 (Table 1).
Women with type 1 diabetes only had
higher concentrations of IL-6 (Table 2).
In type 1 diabetes, univariate correla-
tions showed that aPWV correlated pos-
itively with age, BMI, waist, waist-to-hip
ratio, SBP, MAP, and total and LDL cho-
lesterol (Table 3). In healthy subjects,
aPWV was associated with age, BMI, waist,
total and LDL cholesterol, and fasting
plasma glucose. In men with type 1 diabe-
tes, aPWV correlated positively with
hsCRP (r = 0.389; P = 0.031) and IL-6
(r = 0.447; P = 0.008). However, no sig-
nificant association between aPWV and
inflammatory-related serum proteins was







Age (years) 35.6 (9.0) 36.5 (8.9) 0.963
Alcohol intake (g/day) 2.9 (0–7.1) 5.7 (2.9–15.0) 0.008
Current smokers [n (%)] 7 (20.6) 12 (35.3) 0.089




Family history of coronary
heart disease [n (%)] 2 (5.9) 2 (5.9) 1.000
Family history of type 2
diabetes [n (%)] 5 (14.7) 7 (20.6) 0.525
Family history of type 1
diabetes [n (%)] 0 (0) 2 (5.9) 0.493
Hypertension [n (%)] 3 (8.8) 13 (38.2) 0.004
Dyslipidemia [n (%)] 17 (50.0) 18 (52.9) 0.808
Diabetes duration (years) d 14.00 (8.50–20.50) d
Microvascular complications [n (%)] d 9 (26.5) d
Retinopathy [n (%)] d 5 (14.7) d
None [n (%)] d 29 (85.3) d
Nonproliferative [n (%)] d 4 (11.8) d
Proliferative [n (%)] d 1 (2.9) d
Nephropathy [n (%)] d 6 (17.6) d
Peripheral polyneuropathy [n (%)] d 0 (0) d
BMI (kg/m2) 25.0 (2.8) 26.1 (3.3) 0.138
Waist (cm) 91.0 (10.1) 90.6 (11.3) 0.862
Waist-to-hip ratio 0.90 (0.10) 0.91 (0.07) 0.532
SBP (mmHg) 124.9 (9.5) 131.7 (10.8) 0.008
DBP (mmHg) 73.8 (8.0) 76.7 (7.0) 0.124
MAP (mmHg) 90.8 (8.1) 95.0 (7.3) 0.029
Fasting plasma glucose (mmol/L) 4.76 (0.57) 8.71 (3.76) ,0.001
Total cholesterol (mmol/L) 5.08 (1.54) 4.74 (0.82) 0.260
Triglycerides (mmol/L) 0.88 (0.69–1.29) 0.83 (0.69–1.14) 0.585
HDL cholesterol (mmol/L) 1.31 (1.13–1.49) 1.31 (1.11–1.76) 0.560
LDL cholesterol (mmol/L) 2.81 (2.26–3.59) 2.61 (2.23–3.13) 0.213
HbA1c (%) 5.4 (5.1–5.5) 7.3 (6.6–7.9) ,0.001
Urinary albumin-to-creatinine
ratio (mg/mmol) 0.39 (0.30–0.51) 0.28 (0.20–0.47) 0.125
aPWV (m/s) 6.3 (5.7–6.7) 6.9 (6.5–7.9) ,0.001
hsCRP (mg/L) 0.6 (0.3–1.1) 1.2 (0.5–2.9) 0.036
IL-6 (pg/mL) 0.3 (0.2–0.6) 0.6 (0.3–1.0) 0.002
sTNFaR1 (pg/mL) 1,410 (1,113–2,308) 2,739 (1,748–3,224) ,0.001
sTNFaR2 (pg/mL) 2,060 (1,870–2,365) 2,774 (2,267–3,064) ,0.001
Data are percentages, means (SD), or medians (interquartile range), unless otherwise indicated.
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found in healthy control subjects (men
and women) or in women with type 1 di-
abetes. In women with type 1 diabetes,
aPWV correlated positively with diabetes
duration (r = 0.538; P = 0.001). No asso-
ciation between aPWV and chronic diabe-
tes complications was found either in men
or women.
To evaluate the main predictors of
aPWV,multiple linear regression analyses
were performed. Inflammatory-related se-
rum proteins were tested in all these
models as well as the low-grade inflam-
mation general score previously described.
In men, the best multiple linear regression
model showed that the independent pre-
dictors of aPWV were age, BMI, type 1 di-
abetes, and the low-grade inflammation
general score (R2 = 0.543; P, 0.001). In
women, age, BMI, MAP, and type 1 dia-
betes were the independent predictors for
aPWV (R2 = 0.550; P , 0.001) (Table 4).
Even after adjusting for metabolic control
(logHbA1c) these results did not change.
CONCLUSIONSdThe main finding
of the current study is that arterial stiff-
ness (assessed as aPWV) is increased in
subjects with type 1 diabetes compared
with age- and sex-matched healthy sub-
jects, even after controlling for classic car-
diovascular risk factors. Of note is the fact
that our study suggests an association, for
the first time, between arterial stiffness and
low-grade inflammation inmenwith type 1
diabetes.
Our results confirm, and reinforce
in a larger population, previous studies
showing an increase in arterial stiffness
assessed as aPWV in adult subjects with
type 1 diabetes when comparedwith healthy
subjects (21,22). We also found that pa-
tients with type 1 diabetes have higher
concentrations of inflammatory-related
serum proteins than healthy control sub-
jects, as previously reported in several stud-
ies (23,24). Men with type 1 diabetes had
higher concentrations of hsCRP, IL-6,
sTNFaR1, and sTNFaR2 than their con-
trol subjects. However, women only
showed differences for IL-6. Despite
these discrepancies, we found no differ-
ences between sexes within the same
group. Previous studies have found
higher inflammatory parameters in type
1 diabetic women than in men (24–26).
Nevertheless, other authors have failed to
report such differences, which agrees
with our results (27–29).
Our study shows, for the first time, an
association between arterial stiffness and
low-grade inflammation in subjects with
type 1 diabetes.We have observed thatmen
with type 1 diabetes have higher aPWV and
higher concentrations of inflammatory-
related serum proteins than control sub-
jects. When we adjusted these data, a
general score of low-grade inflamma-
tion was an independent predictor of
aPWV, taking into account diabetes status.
Similar associations between aPWV and
inflammatory-related serum proteins have
been previously reported in healthy indi-
viduals (12), in hypertensive subjects
(13), in subjects with chronic kidney dis-
ease (14), and in individuals with meta-
bolic syndrome (15) for both sexes.
However, we only observed this associa-
tion in men. Tsioufis et al. (30) reported
similar results in hypertensive patients.
They found that hsCRP and adiponectin
were independent predictors of aPWV
only in men. Colhoun et al. (31) reported
that hsCRP was independently associated
with coronary artery calcification (a vali-
dated measure of coronary atherosclero-
sis) only in men with type 1 diabetes.







Age (years) 35.3 (11.4) 35.2 (11.2) 0.971
Alcohol intake (g/day) 1.4 (0–2.9) 0.0 (0.0–0.7) 0.001







Family history of coronary
heart disease [n (%)] 4 (11.8) 1 (2.9) 0.356
Family history of type 2
diabetes [n (%)] 7 (20.6) 9 (26.5) 0.567
Family history of type 1
diabetes [n (%)] 1 (2.9) 3 (8.8) 0.614
Hypertension [n (%)] 0 (0) 4 (11.8) 0.114
Dyslipidemia [n (%)] 17 (50) 14 (41.2) 0.465
Diabetes duration (years) d 12.00 (6.75–18.00) d
Microvascular complications [n (%)] d 7 (20.6) d
Retinopathy [n (%)] d 5 (14.7) d
None [n (%)] d 29 (85.3) d
Nonproliferative [n (%)] d 2 (5.9) d
Proliferative [n (%)] d 3 (8.8) d
Nephropathy [n (%)] d 3 (8.8) d
Peripheral polyneuropathy [n (%)] d 0 (0) d
BMI (kg/m2) 23.0 (3.1) 25.3 (3.9) 0.009
Waist (cm) 76.3 (6.9) 80.0 (10.3) 0.092
Waist-to-hip ratio 0.80 (0.06) 0.81 (0.07) 0.529
SBP (mmHg) 116.3 (9.5) 118.3 (9.6) 0.379
DBP (mmHg) 67.9 (7.8) 69.1 (7.9) 0.508
MAP (mmHg) 84.0 (7.9) 85.5 (7.5) 0.417
Fasting plasma glucose (mmol/L) 4.59 (0.48) 9.59 (3.55) ,0.001
Total cholesterol (mmol/L) 5.18 (1.11) 4.82 (0.92) 0.146
Triglycerides (mmol/L) 0.72 (0.56–0.93) 0.70 (0.53–0.84) 0.484
HDL cholesterol (mmol/L) 1.77 (1.46–1.99) 1.80 (1.49–2.20) 0.377
LDL cholesterol (mmol/L) 2.78 (2.18–3.48) 2.47 (1.90–2.97) 0.056
HbA1c (%) 5.3 (5.2–5.4) 7.8 (7.1–9.1) ,0.001
Urinary albumin-to-creatinine
ratio (mg/mmol) 0.38 (0.27–0.65) 0.47 (0.30–0.91) 0.315
aPWV (m/s) 6.0 (5.3–6.7) 6.4 (5.9–7.5) 0.023
hsCRP (mg/L) 0.9 (0.4–2.8) 1.4 (0.7–2.5) 0.447
IL-6 (pg/mL) 0.4 (0.2–0.6) 0.6 (0.3–1.2) 0.039
sTNFaR1 (pg/mL) 1,917 (1,355–3,295) 2,262 (1,366–2,978) 0.864
sTNFaR2 (pg/mL) 2,215 (1,897–2,700) 2,295 (2,018–3,006) 0.320
Data are percentages, means (SD), or medians (interquartile range), unless otherwise indicated.
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These results indicate that more studies
are needed to elucidate the potential gen-
der differences in the pathophysiology of
cardiovascular disease in type 1 diabetes.
The exact mechanisms responsible
for the increase in arterial stiffness in type
1 diabetes are not fully understood but are
likely to reflect a complex interaction
between structural and functional
changes in the arterial wall. The struc-
tural changes are characterized by an
overproduction of abnormal collagen
and diminished quantities of normal
elastin (32). Our results suggest that
low-grade inflammation could play a
role in the increase of arterial stiffness
in type 1 diabetes. However, other
mechanisms, such as the accumulation
of advanced glycation end products and
endothelial dysfunction, also could be
involved (32).
Low-grade inflammation has been
associated with the presence of a worse
cardiovascular profile (33) and the pres-
ence of micro- andmacrovascular compli-
cations in subjects with type 1 diabetes
(11). Prospective studies also have demon-
strated the predictive value of low-grade
inflammation in the development of
chronic complications in this disease (34).
Our study would be in agreement with
these results, arterial stiffness being an early
sign of arteriosclerosis.
aPWV predicts cardiovascular events
and total and cardiovascular mortality in
the general population, in the elderly, in
patients with hypertension, in subjects
with end-stage renal failure, and in sub-
jects with type 2 diabetes (5). The inde-
pendent predictive value of arterial
stiffness has been demonstrated after ad-
justment for classical cardiovascular risk
factors. This suggests that arterial stiffness
measurement could add a value to the
classical cardiovascular risk factors in
the prediction of cardiovascular risk
(35). This may be explained by the fact
that arterial stiffness integrates the dam-
age of cardiovascular risk factors (classical
and nonclassical) on the aortic wall over a
long period of time, whereas cardiovascu-
lar risk factors can fluctuate in time, and
their values, recorded at the time of risk
assessment, may not reflect their real im-
pact in damaging the arterial wall (4).
However, prospective studies are needed
to establish the prognosis value of
aPWV in subjects with type 1 diabetes
regarding cardiovascular events. To the
best of our knowledge, only one recent
prospective study has evaluated the
relationship between central arterial
stiffness and the prediction of cardio-
vascular events in type 1 diabetes. This
study showed that central PP was more
strongly associated with the prediction
of cardiovascular events than AIx, but
neither data on aPWV nor markers of
low-grade inflammation were reported
(36).
Table 3dSpearman correlation coefficients for the association between aPWV and








Age (years) 0.598 (,0.001) 0.515 (0.003) 0.577 (0.005) 0.621 (,0.001)
Smoking (no/yes) 0.248 (0.158) 0.113 (0.537) 0.266 (0.128) 20.152 (0.391)
Physical activity 20.257 (0.142) 0.077 (0.677) 0.262 (0.354) 20.004 (0.983)
BMI (kg/m2) 0.439 (0.009) 0.515 (0.002) 0.542 (0.001) 0.412 (0.015)
Waist (cm) 0.461 (0.006) 0.567 (,0.001) 0.620 (0.001) 0.541 (0.001)
Waist-to-hip ratio 0.436 (0.010) 0.412 (0.016) 0.213 (0.227) 0.385 (0.024)
SBP (mmHg) 0.249 (0.156) 0.364 (0.037) 0.158 (0.371) 0.528 (0.001)
DBP (mmHg) 0.282 (0.106) 0.279 (0.122) 0.235 (0.182) 0.490 (0.003)
MAP (mmHg) 0.275 (0.115) 0.3470 (0.009) 0.280 (0.109) 0.547 (0.001)
Cholesterol (mmol/L) 0.534 (0.001) 0.498 (0.004) 0.404 (0.018) 0.393 (0.021)
Triglycerides
(mmol/L) 0.498 (0.003) 0.017 (0.922) 0.259 (0.139) 20.113 (0.525)
HDL (mmol/L) 0.019 (0.914) 20.70 (0.695) 0.154 (0.384) 0.323 (0.062)
LDL (mmol/L) 0.578 (,0.001) 0.460 (0.009) 0.366 (0.033) 0.400 (0.019)
Fasting plasma
glucose (mmol/L) 0.465 (0.006) 0.153 (0.389) 0.380 (0.026) 0.137 (0.440)
HbA1c (%) 0.218 (0.215) 0.177 (0.316) 0.328 (0.059) 0.048 (0.786)
hsCRP (mg/L) 0.010 (0.958) 0.389 (0.031) 0.203 (0.249) 0.037 (0.836)
IL-6 (pg/mL) 0.125 (0.482) 0.447 (0.008) 0.225 (0.202) 20.183 (0.316)
sTNFaR1 (pg/mL) 0.264 (0.167) 0.204 (0.298) 0.255 (0.145) 0.077 (0.664)
sTNFaR2 (pg/mL) 0.070 (0.694) 0.163 (0.407) 0.295 (0.107) 0.224 (0.203)
Low-grade
inflammation
score 0.248 (0.179) 0.369 (0.035) 0.321 (0.083) 0.051 (0.776)
Data are Spearman correlation coefficients (P value).
Table 4dIndependent aPWV predictors for the whole population (by sex)
B (unstandardized) SD b (standardized) P
Men
log aPWV (R = 0.737; R2 = 0.543)
Constant 0.586 0.054 d ,0.001
Age 0.003 0.001 0.351 0.001
Low-grade inflammation score 0.028 0.011 0.287 0.019
BMI 0.005 0.002 0.225 0.024
Type 1 diabetes 0.030 0.014 0.246 0.035
Women
log aPWV (R = 0.741; R2 = 0.550)
Constant 0.377 0.085 d ,0.001
Age 0.004 0.001 0.509 ,0.001
BMI 0.005 0.002 0.227 0.018
MAP 0.002 0.001 0.202 0.032
Type 1 diabetes 0.028 0.014 0.182 0.047
The following variables were adjusted for in this model: age, smoking, physical activity, hypertension (no/
yes), dyslipidemia (no/yes), BMI, MAP, total cholesterol, log triglycerides, logHDL cholesterol, type 1 di-
abetes, and low-grade inflammation score. Only significant variables are shown in the table.
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The major limitation of our study is
its cross-sectional design, which makes
it impossible to determine the temporal
ordering of the association between
arterial stiffness and increased levels of
inflammatory-related serum proteins. In
addition, its observational design does
not allow us to ensure complete control of
all the potential (unknown) confounding
factors. The concentrations of the inflam-
matory-related serum proteins were mea-
suredonly once,whichmightunderestimate
the association between them and arte-
rial stiffness. Nevertheless, it should be
noted that the low-grade inflammation
general score was independently associ-
ated with aPWV in the multiple regres-
sion analyses.
In conclusion, our study demon-
strates that aPWV is increased in subjects
with type 1 diabetes compared with age-
and sex-matched healthy subjects, even
after controlling for classical cardiovascu-
lar risk factors. This suggests that the
measurement of arterial stiffness could
provide some additional information re-
garding cardiovascular risk in type 1 dia-
betes. Finally, our study shows, for the
first time, that arterial stiffness is associ-
ated with an increase in inflammatory-
related serum proteins in men with type 1
diabetes. Our findings suggest that arte-
rial stiffness measurement is a useful tool
for detecting subclinical arteriosclerosis
and making a better cardiovascular pre-
diction in type 1 diabetes. Additional stud-
ies exploring not only the link between
arterial stiffness and low-grade inflamma-
tion but also its potential therapeutic im-
plications are needed.
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